Marianne Jane Shawe-Taylor

Jun 6, 2024 | onlinelibrary.wiley.com | Aderonke T Abiodun |Marianne Jane Shawe-Taylor |Sara Tyebally |Emmanouil Bagkeris

Introduction Fluoropyrimidines including 5-fluorouracil (5-FU) and capecitabine are the third most common cancer treatment class used worldwide.1 They form the basis of chemotherapy treatment for gastrointestinal malignancies, breast, pancreatic and head and neck cancers.2-4 For many patients who develop complications with 5-FU, alternative cancer treatment options are very limited, particularly in colorectal cancer where 5-FU is a backbone of first- and second-line chemotherapy, and...

Apr 18, 2024 | biorxiv.org | Giulia Dowgier |Agnieszka Hobbs |David A. Greenwood |Marianne Jane Shawe-Taylor

AbstractEmerging SARS-CoV-2 variants require rapid assessments of pathogenicity and evasion of existing immunity to inform policy. A crucial component of these assessments is accurate estimation of serum neutralising antibody titres using cultured live virus isolates.

Mar 11, 2024 | thelancet.com | Marianne Jane Shawe-Taylor |David A. Greenwood |Agnieszka Hobbs |Giulia Dowgier

On Dec 13, 2023, WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) reiterated their guidance1WHOStatement on the antigen composition of COVID-19 vaccines. from May, 2023, recommending updating vaccines to better induce neutralising antibodies against the omicron XBB.1 lineage and its descendants that were in circulation at the time.